本文關(guān)鍵詞： Meta分析 心力衰竭 竇性心律 血栓形成　出處：《廣西醫(yī)科大學(xué)》2017年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的:探索竇性心律心力衰竭患者最佳的預(yù)防血栓形成的方案。方法:對(duì)PubMed、EMbase、CNKI、VIP、萬(wàn)方等數(shù)據(jù)庫(kù)進(jìn)行檢索,搜集有關(guān)比較竇性心律心力衰竭患者使用華法林與阿司匹林進(jìn)行預(yù)防血栓形成的研究,并對(duì)搜集到的文章進(jìn)行綜合定量評(píng)價(jià),應(yīng)用Rev Man5.3軟件對(duì)所收集的文獻(xiàn)進(jìn)行Meta分析,觀察的終點(diǎn)事件指標(biāo)包括:全因死亡、缺血性腦卒中、心肌梗死、大出血事件、中樞神經(jīng)系統(tǒng)出血、小出血事件、不良胃腸道反應(yīng)等。結(jié)果:共納入6篇文獻(xiàn),累計(jì)病例3662例,其中華法林組1824例,阿司匹林組1838例。meta分析結(jié)果提示,在預(yù)防竇性心律心力衰竭患者血栓形成的藥物中,華法林組與阿司匹林組在全因死亡(RR=1.01,95%CI0.89~1.14,P=0.88)、心肌梗死(RR=1.09,95%CI 0.74~1.61,P=0.67)、因心衰住院(RR=0.90,95%CI 0.64~1.26,P=0.60)、中樞神經(jīng)系統(tǒng)出血(RR=1.34,95%CI 0.63~2.82,P=0.45)、包括出血在內(nèi)的不良胃腸道反應(yīng)(RR=1.10,95%CI 0.23~5.30,P=0.91)的發(fā)生率的比較上無(wú)統(tǒng)計(jì)學(xué)差異。在缺血性腦卒中的發(fā)生率比較上,華法林顯著低于阿司匹林(RR=0.49,95%CI 0.33~0.73,P=0.0005);然而,在大出血(RR=1.93,95%CI 1.38~2.68,P=0.0001)、小出血(RR=1.37,95%CI 1.11~1.68,P=0.003)的發(fā)生率上,華法林亦明顯高于阿司匹林。結(jié)論:在預(yù)防竇性心律心力衰竭患者血栓形成的治療中,與阿司匹林相比,華法林治療后缺血性腦卒中的發(fā)生率更低,但小出血事件、大出血事件的發(fā)生率更高。
[Abstract]:Objective: to explore the best scheme to prevent thrombosis in patients with sinus heart failure. A comparative study on the use of warfarin and aspirin in prevention of thrombosis in patients with sinus heart failure was collected. The collected articles were evaluated quantitatively and analyzed by Meta using Rev Man5.3 software. The endpoint events included: total death, ischemic stroke, myocardial infarction, massive hemorrhage, central nervous system hemorrhage, small hemorrhage events, adverse gastrointestinal reactions, etc. Results: a total of 6 literatures were included, with a total of 3662 cases. The results of meta analysis in the warfarin group (1824 cases) and aspirin group (1838 cases) suggested that in the prevention of thrombosis in patients with sinus heart failure, There was no statistical difference between warfarin group and aspirin group in the incidence of RRN 1.01c95CI0.89 1.14P0.88, myocardial infarction 1.0995CI 0.749.95 CI 0.741P0.67m, RRRN 0.9095 CI 0.641.26P0.60, central nervous system hemorrhage 1.34495CI 0.632.82P0.45, including hemorrhage. There was no statistical difference in the incidence of adverse gastrointestinal reaction (RRN 1.1095CI 0.235.30P0.91). Compared with the incidence of ischemic stroke, Warfarin was significantly lower than that of Aspirin RRN 0.4995 CI 0.330.73 P0. 0005; however, warfarin was also significantly higher than aspirin in the incidence of RRN 1.9395 CI 1.38C 2.68 P0.0001, RRN 1.37 ~ 95CI 1.111.68 P0.003). Conclusion: in the treatment of prevention of thrombosis in patients with sinus heart failure, warfarin is also significantly higher than aspirin in the prevention of thrombosis in patients with sinus heart failure. Compared with aspirin, the incidence of ischemic stroke after warfarin treatment was lower, but the incidence of small hemorrhage events and massive hemorrhage events was higher.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R541.6

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 馮日清;韋育林;劉英梅;邱瓊;鄧冰清;呂函璐;;竇性心律心力衰竭患者抗凝治療預(yù)后的meta分析[J];嶺南急診醫(yī)學(xué)雜志;2016年02期

2 李文靜;畢亞艷;;心力衰竭患者血液高凝狀態(tài)的機(jī)制及抗栓治療[J];醫(yī)學(xué)綜述;2014年18期

3 王菁菁;;慢性心力衰竭患者抗凝治療的Meta分析[J];中國(guó)地方病防治雜志;2014年S1期

4 匡曉暉;韓明華;;慢性心力衰竭的抗凝治療[J];醫(yī)學(xué)綜述;2013年04期

5 戴天醫(yī);劉小慧;;心力衰竭患者高凝狀態(tài)與抗栓治療[J];臨床藥物治療雜志;2012年06期

6 朱倫華;;法華林和阿司匹林治療房顫的療效對(duì)比分析[J];中國(guó)醫(yī)藥指南;2012年24期

7 ;中國(guó)缺血性腦卒中和短暫性腦缺血發(fā)作二級(jí)預(yù)防指南2010[J];中華神經(jīng)科雜志;2010年02期

，

本文編號(hào)：1504171